文献速递中毒与环境急症儿科与产科急症重症综合管理与镇静镇痛

2002-2016年地区中毒控制中心报告的含蝇伞菌醇和鹅膏蕈氨酸蘑菇中毒

Toxicity of muscimol and ibotenic acid containing mushrooms reported to a regional poison control center from 2002-2016.
PubMed 文献 · Clin Toxicol (Phila) · 2018-08-03
一句话结论含蝇伞菌醇和鹅膏蕈氨酸的蘑菇中毒常表现为胃肠道不适、中枢兴奋和中枢抑制,豹斑鹅膏中毒症状发生率高于毒蝇鹅膏,无死亡报告。

该研究为2002-2016年美国某地区中毒控制中心的回顾性综述,纳入34例经真菌学家鉴定或明确描述为毒蝇鹅膏的摄入病例。其中毒蝇鹅膏23例、豹斑鹅膏10例、A. aprica 1例。25例有症状,除1例外均在6小时内出现症状;豹斑鹅膏摄入后胃肠道症状(80% vs 35%)、中枢抑制(70% vs 35%)和中枢兴奋(70% vs 35%)的发生率均高于毒蝇鹅膏。5例气管插管,1例3岁男童摄入豹斑鹅膏后出现呕吐、激越和嗜睡,接受苯二氮䓬类药物并插管、ICU住院3天。无低血压、癫痫发作、急性肾损伤或肝毒性,无死亡报告。

要点

  • 34例中豹斑鹅膏10例,其胃肠道症状(80% vs 35%)、中枢抑制(70% vs 35%)和中枢兴奋(70% vs 35%)发生率均高于毒蝇鹅膏23例。
  • 25例有症状者中,除1例外均在摄入后6小时内出现症状;15例症状持续不足24小时,6例不足6小时。
  • 5例接受气管插管;1例3岁男童摄入豹斑鹅膏后呕吐、激越、嗜睡,接受苯二氮䓬类药物并插管,ICU住院3天。
  • 意外摄入的儿童病例中4例(25%)有症状,但摄入毒蝇鹅膏的有症状儿童均无需住院。
  • 全部病例无低血压、癫痫发作、急性肾损伤或肝毒性,无死亡报告。

适用人群与场景

  • 2002-2016年向美国某地区中毒控制中心报告的含蝇伞菌醇和鹅膏蕈氨酸蘑菇摄入者,包括觅食(12例)、娱乐性(6例)、意外(12例)、治疗性(1例)、自伤(1例)和未知原因(2例)摄入。
  • 纳入标准为经真菌学家鉴定或明确描述为毒蝇鹅膏的病例。

处置流程与药物剂量

  • 1例3岁男童摄入豹斑鹅膏后出现呕吐、激越和嗜睡,接受苯二氮䓬类药物,随后气管插管并ICU住院3天。

红旗征与不能漏的情况

  • 摄入豹斑鹅膏后出现中枢抑制(70%)或中枢兴奋(70%)需警惕,本研究中5例接受气管插管。
  • 儿童意外摄入豹斑鹅膏可出现呕吐、激越、嗜睡,需气道保护和ICU监护。

研究设计与关键结果

  • 回顾性综述纳入34例,毒蝇鹅膏23例、豹斑鹅膏10例、A. aprica 1例;25例有症状。
  • 豹斑鹅膏较毒蝇鹅膏更常出现任何胃肠道症状(80% vs 35%)、中枢抑制(70% vs 35%)和中枢兴奋(70% vs 35%)。
  • 除1例外所有有症状者均在摄入后6小时内出现症状;15例症状持续不足24小时,6例不足6小时。
  • 5例气管插管;无低血压、癫痫发作、急性肾损伤或肝毒性,无死亡报告。

证据类型、等级与局限

  • 证据类型:回顾性综述。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对摄入含蝇伞菌醇和鹅膏蕈氨酸蘑菇者,应在摄入后6小时内评估胃肠道、中枢兴奋和中枢抑制症状,因除1例外所有有症状者均在此期间出现症状。
  • 豹斑鹅膏摄入者胃肠道和中枢神经系统症状发生率高于毒蝇鹅膏,需更积极评估气道和神经系统状态。
  • 有症状的毒蝇鹅膏儿童摄入者本研究中均无需住院,但豹斑鹅膏摄入儿童可出现需插管和ICU监护的严重症状。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Amanita muscaria (AM) and A. pantherina (AP) contain ibotenic acid and muscimol and may cause both excitatory and sedating symptoms. Gastrointestinal (GI) symptoms are not classically described but have been reported. There are relatively few reported cases of poisoning with these mushrooms in North America.

METHODS: This is a retrospective review of ingestions of ibotenic acid and muscimol containing mushrooms reported to a United States regional poison center from 2002-2016. Cases were included if identification was made by a mycologist or if AM was clearly described.

RESULTS: Thirty-four cases met inclusion criteria. There were 23 cases of AM, 10 AP, and 1 A. aprica. Reason for ingestion included foraging (12), recreational (6), accidental (12), therapeutic (1), self-harm (1), and unknown (2). Of the accidental pediatric ingestions 4 (25%) were symptomatic. None of the children with a symptomatic ingestion of AM required admission. A 3-year-old male who ingested AP had vomiting, agitation, and lethargy and received benzodiazepines. He was intubated and had a 3-day ICU stay. There were 25 symptomatic patients. All but one patient developed symptoms within 6 h. Six patients had symptoms for less than 6 h while 15 had symptoms lasting less than 24 h. Ingestions of AP were more symptomatic than AM with regard to the presence of any GI symptoms (80% vs. 35%), central nervous system (CNS) depression (70% vs. 35%), and CNS excitation (70% vs. 35%) respectively. Five patients were intubated. No patients experienced hypotension, seizures, acute kidney injury, or hepatotoxicity. No deaths were reported.

DISCUSSION: Ingestion of ibotenic acid/muscimol containing mushrooms often produces a syndrome with GI upset, CNS excitation, and CNS depression either alone or in combination. Ingestion of AP was associated with a higher rate of symptoms compared to AM.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Moss MJ, Hendrickson RG. Toxicity of muscimol and ibotenic acid containing mushrooms reported to a regional poison control center from 2002-2016. Clin Toxicol (Phila). 2018. PMID: 30073844. doi:10.1080/15563650.2018.1497169

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。